Group 1 - The core point of the article is the establishment of a new company, 亚宝药业（600351）(广东横琴)有限公司, with a registered capital of 100 million yuan, focusing on medical research, biotechnology product development, and bio-based material polymer technology research [1] - The new company is jointly held by 亚宝药业 and 亚宝药业(澳门)有限公司, indicating a strategic partnership in expanding their business operations [1] - The operational scope of the new company includes medical research and experimental development, which aligns with current trends in the biotechnology sector [1]

Group 1 - The establishment of Guotou Biological Manufacturing Innovation Research Institute (Wuxi) Co., Ltd. has been announced, with a registered capital of 30 million yuan [1] - The company's business scope includes research and development of bio-based materials technology, production process of biomass liquid fuels, bio-chemical products technology, and artificial intelligence theory and algorithm software development [1] - The company is jointly held by the wholly-owned subsidiary of China National Development Investment Corporation and Wuxi Life Science Industry Development Co., Ltd. [1]